ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

This trial is testing a combination of two drugs — ZEN003694 (a BET inhibitor) and talazoparib (a PARP inhibitor) — in women with ovarian cancer that has come back after prior treatment. **You may be eligible if...** - You are a woman aged 18 or older with ovarian, fallopian tube, or peritoneal cancer that has returned - You have previously been treated with a PARP inhibitor - You have at least one measurable tumor - You know your BRCA1/2 gene status - Your blood counts and organ function are within acceptable ranges - You are post-menopausal or using highly effective contraception **You may NOT be eligible if...** - You have severe liver or kidney impairment - You are pregnant or breastfeeding - You have an active serious infection or autoimmune condition - You have recently had a blood transfusion (within 4 weeks) Talk to your doctor to see if this trial is right for you.